Lima SM, Kehm RD, Terry MB. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine. 2021;38:100985.

Article  PubMed  PubMed Central  Google Scholar 

Gremke N, Wagner U, Kalder M, Kostev K. Changes in the incidence of early-onset breast cancer in Germany between 2010 and 2022. Breast Cancer Res Treat. 2023;202:167–72.

Article  PubMed  PubMed Central  Google Scholar 

Robert Koch Institute (RKI). Breast cancer [Internet]. Robert Koch Institute. Available from: https://www.krebsdaten.de/Krebs/EN/Content/Cancer_sites/Breast_cancer/breast_cancer_node.html . Accessed 10 Jan 2024.

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:611–35.

Article  CAS  Google Scholar 

Schmidt ME, Scherer S, Wiskemann J, Steindorf K. Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life. Eur J Cancer Care (Engl). 2019;28:e13051.

Article  PubMed  Google Scholar 

Kang D, Kim H, Cho J, Kim Z, Chung M, Lee JE, et al. Prediction Model for postoperative quality of life among breast cancer survivors along the survivorship trajectory from pretreatment to 5 years: machine learning-based analysis. JMIR Public Health Surveill. 2023;9:e45212.

Article  PubMed  PubMed Central  Google Scholar 

Lovelace DL, McDaniel LR, Golden D. Long-term effects of breast cancer surgery, treatment, and survivor care. J Midwifery Womens Health. 2019;64:713–24.

Article  PubMed  Google Scholar 

Maurer T, Thöne K, Obi N, Jung AY, Behrens S, Becher H, et al. Health-related quality of life in a cohort of breast cancer survivors over more than 10 years post-diagnosis and in comparison to a control cohort. Cancers. 2021;13(8):1854.

Article  PubMed  PubMed Central  Google Scholar 

Di Meglio A, Havas J, Gbenou AS, Martin E, El-Mouhebb M, Pistilli B, et al. Dynamics of long-term patient-reported quality of life and health behaviors after adjuvant breast cancer chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40:3190–204.

Article  Google Scholar 

Carmona-Bayonas A, Calderón C, Hernández R, Fernández Montes A, Castelo B, Ciria-Suarez L, et al. Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy. NPJ Breast Cancer. 2021;7:92.

Article  PubMed  PubMed Central  Google Scholar 

Cocchiara RA, Sciarra I, D’Egidio V, Sestili C, Mancino M, Backhaus I, et al. Returning to work after breast cancer: a systematic review of reviews. Work Read Mass. 2018;61:463–76.

CAS  Google Scholar 

Sun Y, Shigaki CL, Armer JM. Return to work among breast cancer survivors: a literature review. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2017;25:709–18.

Google Scholar 

Kim DY, Youn J-C, Park M-S, Lee S, Choi S-W, Ryu K-H, et al. Cardiovascular outcome of breast cancer patients with concomitant radiotherapy and chemotherapy: a 10-year multicenter cohort study. J Cardiol. 2019;74:175–81.

Article  PubMed  Google Scholar 

Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:3325–48.

Article  Google Scholar 

Kim S-D, Kwag E-B, Yang M-X, Yoo H-S. Efficacy and safety of ginger on the side effects of chemotherapy in breast cancer patients: systematic review and meta-analysis. Int J Mol Sci. 2022;23(19):11267.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Nardo P, Lisanti C, Garutti M, Buriolla S, Alberti M, Mazzeo R, et al. Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects. Expert Opin Drug Saf. 2022;21:1341–55.

Article  PubMed  Google Scholar 

Jacob SL, Huppert LA, Rugo HS. Role of immunotherapy in breast cancer. JCO Oncol Pract. 2023;19:167–79.

Article  PubMed  Google Scholar 

Criscitiello C, Corti C, Pravettoni G, Curigliano G. Managing side effects of immune checkpoint inhibitors in breast cancer. Crit Rev Oncol Hematol. 2021;162:103354.

Article  PubMed  Google Scholar 

Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:119–42.

Article  Google Scholar 

Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I, Grivas P, et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:724–44.

Article  CAS  Google Scholar 

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet Lond Engl. 2013;381:805–16.

Article  CAS  Google Scholar 

Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage. 2002;23:501–9.

Article  PubMed  Google Scholar 

Cathcart-Rake EJ, Tevaarwerk AJ, Haddad TC, D’Andre SD, Ruddy KJ. Advances in the care of breast cancer survivors. BMJ. 2023;382:e071565.

Article  PubMed  Google Scholar 

Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22:e303–13.

Article  CAS  PubMed  Google Scholar 

Gallicchio L, Calhoun C, Helzlsouer KJ. Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat. 2013;142:435–43.

Article  CAS  PubMed  Google Scholar 

Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:1601–10.

Article  CAS  Google Scholar 

Kotecki N, Penel N, Awada A. Metabolic disorders associated with the use of targeted cancer therapies. Curr Opin Oncol. 2015;27:258–66.

Article  CAS  PubMed  Google Scholar 

Al‑Ghabban A, Al‑Shibany A, Al‑Shangiti K, Aseafan M, Latif K, Al‑Tweigeri T. Adjuvant abemaciclib‑induced pneumonitis: a case report and review of the literature. World Acad Sci J [Internet]. Available from: https://doi.org/10.3892/wasj.2021.99. Accessed 4 Oct 2024.

Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77–90.

Article  CAS  PubMed  Google Scholar 

Zubor P, Gondova A, Polivka J, Kasajova P, Konieczka K, Danko J, et al. Breast cancer and Flammer syndrome: any symptoms in common for prediction, prevention and personalised medical approach? EPMA J. 2017;8:129–40.

Article  PubMed  PubMed Central  Google Scholar 

Golubnitschaja O, editor. Flammer syndrome: from phenotype to associated pathologies, prediction, prevention and personalisation [Internet]. Cham: Springer International Publishing. Available from: https://doi.org/10.1007/978-3-030-13550-8 . Accessed 4 Nov 2024.

Bubnov R, Polivka J, Zubor P, Konieczka K, Golubnitschaja O. “Pre-metastatic niches” in breast cancer: are they created by or prior to the tumour onset? “Flammer Syndrome” relevance to address the question. EPMA J. 2017;8:141–57.

Article  PubMed  PubMed Central  Google Scholar 

Golubnitschaja O. Feeling cold and other underestimated symptoms in breast cancer: anecdotes or individual profiles for advanced patient stratification? EPMA J. 2017;8:17–22.

Article  PubMed  PubMed Central  Google Scholar 

Polivka J, Altun I, Golubnitschaja O. Pregnancy-associated breast cancer: the risky status quo and new concepts of predictive medicine. EPMA J. 2018;9:1–13.

Article  PubMed  PubMed Central  Google Scholar 

Polivka J, Kralickova M, Polivka J, Kaiser C, Kuhn W, Golubnitschaja O. Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon? EPMA J. 2017;8:119–27.

Article  PubMed  PubMed Central